Is CRT‑D superior to CRT‑P in patients with nonischemic cardiomyopathy?
10.1186/s42444-023-00085-3
- Author:
Mohammed AL‑SADAWI
1
;
Faisal ASLAM
;
Michael TAO
;
Shafqat SALAM
;
Mahmoud ALSAIQALI
;
Abhijeet SINGH
;
Roger FAN
;
Eric J. RASHBA
Author Information
1. Stony Brook Heart Rhythm Center, Stony Brook Medicine, Stony Brook Heart Institute, 101 Nicolls Rd, Stony Brook, NY 11794, USA
- Publication Type:REVIEW
- From:International Journal of Arrhythmia
2023;24(1):3-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Recent studies have questioned the role of implanted cardiac defibrillators (ICDs) in nonischemic cardiomyopathy (NICM). Cardiac resynchronization therapy (CRT) can be delivered by a pacemaker (CRT-P) or an ICD (CRT-D). This meta-analysis assessed the effect of CRT-P versus CRT-D on mortality in patients with NICM.
Methods:Databases were searched for studies reporting the effect of CRT on all-cause mortality in patients with nonischemic cardiomyopathy (Ovid MEDLINE, EMBASE, Scopus, Web of Science, Google Scholar, and EBSCO CINAHL). The primary endpoint was all-cause mortality. The minimum duration of follow-up required for inclusion was one year. The search was not restricted to time or publication status.
Results:The literature search identified 955 candidate studies, 15 studies and 22,763 patients were included. Mean follow-up was 53 months (17–100 months). CRT-D in NICM was associated with lower all-cause mortality (log HR − 0.169, SE 0.055; p = 0.002) compared to CRT-P. Heterogeneity: df = 15 (p 0.03), I2 = 43; test for overall effect: Z = − 3.043 (p = 0.002).
Conclusion:CRT-D in NICM was associated with lower all-cause mortality than CRT-P.
